COVID-19 PANDEMIC UPDATES
|
Learn more

Patient blood group impacts susceptibility to IVIg-associated hemolysis

What is this research about?

High-dose intravenous immunoglobulin (IVIg) is given to treat patients with immune and inflammatory diseases. It is usually an effective treatment that is well-tolerated. However, high-dose IVIg can cause an adverse reaction in which the patient’s red blood cells burst (hemolysis). The hemolysis is often mild and self-limiting, but it can become severe. Some patients who develop hemolysis may require transfusion of red blood cells to treat the resulting anemia.

Published on